key: cord-0759040-h8mtmp09
authors: Maghbooli, Zhila; Sahraian, Mohammad Ali; Jamali-Moghadam, Saeid Reza; Asadi, Asma; Azadeh zarei, M.D.; Zendehdel, Abolfazl; Varzandi, Tarlan; Mohammadnabi, Sara; Alijani, Neda; Karimi, Mehrdad; Shirvani, Arash; Holick, Michael F.
title: Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in patients hospitalized with COVID-19: a pilot, multicenter, randomized, placebo-controlled double blind clinical trial
date: 2021-10-13
journal: Endocr Pract
DOI: 10.1016/j.eprac.2021.09.016
sha: 578dc5a7c3d577fe6a1883d4f5d0ba942686b3c9
doc_id: 759040
cord_uid: h8mtmp09

OBJECTIVE: The goal of this randomized placebo-controlled clinical trial was to investigate the therapeutic efficacy of oral 25-hydroxyvitamin D(3) [25(OH)D(3)] in improving vitamin D status in vitamin D deficient/insufficient patients infected with the SARS-CoV-2 (COVID-19) virus. METHODS: This is a multicenter randomized double blinded randomized placebo-controlled clinical trial. Participants were recruited from three hospitals that are affiliated to [Institution Blinded for Review], and [Institution Blinded for Review]. RESULTS: A total 106 hospitalized patients who had a circulating concentration of 25(OH)D <30 ng/ml were enrolled in this study. Within 30 and 60 days 79.4% (26 out of 34) and 100% (24 out of 24) of the patients who received 25(OH)D(3) became sufficient whereas ≤12.5% the patients in the placebo group became sufficient during 2 months follow-up. We observed an overall lower trend for hospitalization, ICU duration, needing ventilator assistance and mortality in the 25(OH)D3 group compared with placebo group but they weren’t statistically significant. Treatment with oral 25(OH)D(3) was associated with a significant increase in the lymphocyte percentage and decrease in the ratio of neutrophils to lymphocytes (NLR) in the patients. The lower NLR was significant associated with reduced ICU admission days and mortality. CONCLUSION: Our analysis indicated that oral 25-hydroxyvitamin D(3) was able to correct vitamin D deficiency/insufficiency in COVID-19 patients that resulted in improved immune function by increasing blood lymphocyte percentage. RCTs with a larger sample size and with higher dose of 25(OH)D3 maybe needed to confirm the potential effect of 25(OH)D3 on reducing clinical outcomes in COVID-19 patients. ETHICS AND DISSEMINATION: The study protocol was approved by the Ethics Committee of [Institution Blinded for Review]. (Approval Number: IR.TUMS.VCR.REC.1399.061). Dissemination plans include academic publications, conference presentations and social media. TRIAL REGISTRATION: The protocol was registered with the Iranian Registry of Clinical Trials (IRCT) on April 11, 2020 [Number Blinded for Review]. and U.S. National Institutes of Health [Number Blinded for Review] on May 11, 2020.

patients who received 25(OH)D3 became sufficient whereas ≤12.5% the patients in the placebo group 38 became sufficient during 2 months follow-up. 39 We observed an overall lower trend for hospitalization, ICU duration, needing ventilator assistance and 40 mortality in the 25(OH)D3 group compared with placebo group but they weren't statistically significant. 

The recruitment was started on May 2020, and the study run until October 2020. All measurements were 108 analyzed at the admission date, release date, and after first-and second month follow-up. 

Based on inclusion criteria, a total 106 vitamin D deficient/insufficient hospitalized patients were enrolled was monitored in each follow-up visit (after 30 days and 60 days of starting 25(OH)D3 or placebo) for a 232 serum concentrations of calcium, albumin, creatinine (Table S1) 

The severity of disease considered based on CDC criteria; dyspnea, respiratory frequency ≥30/minute, 240 blood oxygen saturation < 93%, and/or lung infiltrates >50% of the lung field within 24-48 hours. (Table 3) .

During hospitalization, all patients were treated with hydroxychloroquine and antibiotics (Azithromycin 273 or Ceftriaxone). There was no significant difference between-group in the proportion of patients treated 274 with corticosteroids (less than 10 mg/day dexamethasone, or equal/less than 25mg methyl-prednisolone), 

There was no significant difference in mean changes of platelet number and serum concentrations of LDH 287 between two groups (p=0.96, p=0.57, respectively).

The data analysis showed that there were not any significant differences in re-admission. There was not 289 any mortality in two groups after first-and second-month of follow up.

Regarding to the modifier role of 25(OH)D3 on treatment, the relationship of NLR was considered with 291 main outcomes of COVID-19 including ICU admission days, and mortality.

There was significant correlation between lower NLR and reduced ICU admission days and the NLR 293 (rho=0.3, p=0.004). In a logistic regression model, after adjusting age, sex, BMI and history of chronic 294 disorders, there was independent association between NLR at the time of discharge and needing ICU 295 admission (p=0.002, OR=1.2).

Although in our study population a few patients died, the NLR at the last day of hospitalization was about 297 4 times higher than patients who survived (median (IQR); 15.7(7.7) vs. 3.1(5.1)).

Among biochemical outcomes, there was significant correlation between the NLR and LDH (p=0.02, 299 r=0.3). However, after adjusting age, sex and history of chronic disorders there was no significant 300 association between the NLR and LDH at the time of discharge (p=0.08). 

In a recent meta-analysis by Lagunas-Rangel (31) the NLR values were found to increase in patients 362 with severe COVID-19 with 2.4 efficacy. Consistent with these studies, our data showed the NLR at the 363 time of enrollment was a significant predictor of needing intensive care. Although, only a few patients 364 died in our study, those patients who died had a NLR that was 4 times higher than the NLR at the time the 365 patients were released from the hospital.

Based on these findings 25(OH)D3 intervention was significantly associated with the decreased NLR in 367 the hospitalized COVID-19 patients compared to the hospitalized patients who received the placebo.

Although the decrease in the circulating NLR was associated with improved clinical outcomes, we could 369 not conclude that the decrease in NLR was solely the effect of 25-hydroxyvitamin D3 treatment and, 

Procalcitonin in patients with severe coronavirus disease 2019 465 (COVID-19): A meta-analysis

Comorbidity and its impact on 1590 patients with 468 COVID-19 in China: a nationwide analysis. The European respiratory journal

Vitamin D supplementation to prevent 470 acute respiratory tract infections: systematic review and meta-analysis of individual participant 471 data

Vitamin D sufficiency, a serum 25-473 hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with 474 COVID-19 infection

SARS-CoV-2 positivity rates 476 associated with circulating 25-hydroxyvitamin D levels

Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis. 479 Critical reviews in food science and nutrition

Effect of a Single High Dose of Vitamin D3 on 481 Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized 482 Clinical Trial

Effect of 484 calcifediol treatment and best available therapy versus best available therapy on intensive care 485 unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized 486 clinical study". The Journal of steroid biochemistry and molecular biology

Impact of Vitamin D Supplementation on 490 Influenza Vaccine Response and Immune Functions in Deficient Elderly Persons: A Randomized 491 Placebo-Controlled Trial

Evaluation, treatment, and 496 prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline

Is calcifediol better than cholecalciferol for vitamin D 499 supplementation? Osteoporosis international : a journal established as result of cooperation 500 between the European Foundation for Osteoporosis and the National Osteoporosis Foundation 501 of the USA

Oral supplementation with 506 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood 507 pressure, and markers of innate immunity

Skeletal and Extraskeletal Actions of 512 Vitamin D: Current Evidence and Outstanding Questions

Reduction in 517 circulating vitamin D binding protein in patients with multiple sclerosis

Immunologic Effects of Vitamin D on Human Health and 520 Disease

Cholecalciferol or Calcifediol in the 522 Management of Vitamin D Deficiency

Vitamin D3 and calcidiol are not equipotent. The Journal of steroid biochemistry and molecular 525 biology

Vitamin D and its Major 527 Metabolites: Serum Levels after Graded Oral Dosing in Healthy Men

A pilot-randomized, double-blind 530 crossover trial to evaluate the 531 pharmacokinetics of orally administered 25-hydroxyvitamin D3 and 532 vitamin D3 in healthy adults with differing BMI and in adults with 533 intestinal malabsorption. The American journal of clinical nutrition

Vitamin D and the immune system: new perspectives on an old theme

Is It Time to Consider the Use of Calcifediol? Nutrients. 2019;11. 538 28. Denman AM. Lymphocyte function and virus infections

Patients: A Meta-Analysis. Cytometry Part A : the journal of the International Society for 542 Analytical Cytology

COVID-19 and neutrophils: The 544 relationship between hyperinflammation and neutrophil extracellular traps. Mediators of 545 Inflammation. 2020;2020. 546 31. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-547 reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-548 analysis

Calcifediol Treatment and 550 Hospital Mortality Due to COVID-19: A Cohort Study

Vitamin D and survival in COVID-19 patients: A quasi-experimental study. The Journal of 555 steroid biochemistry and molecular biology

Epidemiological and clinical characteristics of 99 cases 557 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet

Characteristics of and important lessons from the coronavirus 560 disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the 561

Chinese Center for Disease Control and Prevention

Pathological findings of COVID-19 associated with acute 563 respiratory distress syndrome. The Lancet respiratory medicine

Daily oral dosing of vitamin D3 using 5000 TO 565 50,000 international units a day in long-term hospitalized patients: Insights from a seven year 566 experience. The Journal of steroid biochemistry and molecular biology

N=available data for each variable Albumin (Alb), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), blood urea nitrogen (BUN), Body mass index (BMI), calcium (Ca

Treatment group 42.0±2.3 ng/ml, vs. placebo: 19.3±1.7 ng/ml. After 60 days the 633 24 patients in the treatment group had a serum concentration of 25(OH)D of 59.6±3.8 ng/ml

The neutrophil-to-lymphocyte ratio (NLR) in the 25(OH)D3 and placebo groups at the time of 639 hospitalization and after release date

After the patients were released from the 642 hospital, they had a follow-up visit 1 and 2 months later at which time the NLR in their circulation was 643 determined. The circulating NRL decreased in both groups and were statistically no different

The NLR at the first-month follow-up in patients who received 25(OH)D3 (N=33) and placebo (N=28) 645 was 1

After 2 months follow-up, the NLR in the treatment group (N=32) and placebo group (N=22)

The error bars are mean±SE

We appreciate of all health providers, and laboratory staffs of Ziaian Hospital, Shariati Hospital and 436 Shohadaye Pakdasht Hospital. Dishman Carbogen Amcis Ltd as a partner of BU manufactured and

The remaining authors declare that they have no known competing financial interests or personal 452 relationships that could have appeared to influence the work reported in this paper.

Submission declaration and verification

The work described has not been published previously, that it is not under consideration for publication 455 elsewhere. Its publication is approved by all authors and tacitly or explicitly by the responsible authorities 456 where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, 

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:The authors declare the following personal relationships which may be considered as potential competing interests: Michael F. Holick was a consultant for Quest Diagnostics Inc. is a consultant for Ontometrics Inc and Biogena Inc., received a grant from Carbogen Amcis BV and was on the speaker's Bureau for Abbott Inc. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.